What top creators are saying about Eli Lilly and Company(LLY)— Page 2

A primary public proxy for the rapidly growing GLP-1 and peptide market trend.

Bullish outlook due to the expansion of GLP-1 medications into broader chronic disease prevention and metabolic health.

Speculation regarding a potential future partnership with HIMS for peptide-related treatments.

Utilizing AI for massive data set analysis in clinical trials to improve profit margins.

Partnered with Insilico Medicine for AI-driven drug discovery which shows high clinical trial success rates.

Aggressively partnering with AI-first biotech firms like Insilico Medicine to collapse drug discovery timelines.

Key player in the GLP-1 market which is viewed as the entry point for reversing aging.

Leader in AI-driven drug discovery with a recent price reset providing a potential entry point.

Partnering with Amazon Pharmacy for same-day delivery of GLP-1 medications, leveraging Amazon's logistics network to capture the metabolic health market.

Partnership with Amazon Pharmacy for same-day delivery of new GLP-1 pill Foundayo provides a major growth lever.

Developing Retatrutide, a powerful upcoming triple agonist drug currently in Phase 3 trials.

Becoming a 'token factory' by using supercomputers and AI to revolutionize drug discovery.

As GLP-1 drugs gain social momentum, regulatory shifts may create moats for large pharmaceutical companies capable of navigating the clinical trial process.

Potential future distribution partnership with HIMS; competitor in the weight loss pill and peptide market.

Up 4% on news of a new oral weight-loss pill, Fondayo, expanding its market reach.

Showing positive momentum as a notable green performer.

Strategic $2.75 billion collaboration with Insilico Medicine to acquire AI-vetted drug candidates, potentially securing new GLP-1 assets.

Part of the 'health-maxing' and longevity investment theme involving peptides and weight loss.

Included in the curated model portfolio focusing on high-conviction hardware and infrastructure names.

Deeply integrated with the U.S. legislative process and highlighted as a major corporate donor to influential health committee members.

Dominant in weight-loss market with Zepbound; viewed as a long-term winner despite a recent 6% daily dip.

Positioned to benefit from regulatory crackdowns on unregulated peptides and the development of next-generation drugs like Retatrutide.

Potential future partnership with HIMS for retatrutide; HIMS has avoided competing with Lilly's tirzepatide.

Mentioned as a 'usual suspect' in political campaign contributions seeking to maintain Washington influence.

Holds a significant investment moat through patent protection on pharmaceutical chemistry; Retatrutide represents a high-potential next-generation metabolic treatment.

Identified as a primary tradable asset to capture the massive growth in the peptide and weight-loss market.

Collaborating with NVIDIA to utilize AI for drug discovery and R&D pipeline acceleration.

Viewed as brilliant for bypassing Pharmacy Benefit Managers (PBMs) to sell GLP-1 drugs directly to patients.

Positioned as a regulated heavyweight in the biopharmaceutical space with high-demand products like Retatrutide in trials.

Beneficiary of the 'Performance Medicine' trend among high-performers, specifically with its Retatrutide product.

Experiencing a massive revenue boom from next-generation peptides like Terzepatide and the upcoming Retatrutide catalyst.

Faces significant policy risk from federal and state-level price caps on insulin and potential competition from imported drugs.

Viewed as a more transformative investment than AI with significant upside due to health and addiction applications.

Remains a primary mover in the obesity drug market with Retatrutide showing subjects losing up to one-third of body weight in Phase 3 trials.

GLP-1 drugs are viewed as a more transformative economic force than AI, with massive potential to reduce healthcare costs.

Viewed as a potential 'Magnificent 7' member due to leadership in longevity and GLP-1 medications.

Developing Retatrutide, a potential 'game changer' drug that could disrupt the current Semaglutide market.

While facing pricing pressure, the company is actively onshoring manufacturing with six new plants in the U.S.

The normalization of weight loss drugs for non-diabetic use signals a strong bullish trend for the dominant market leaders.

Extremely optimistic view based on its pipeline drug retatrutide, described as a potential 'miracle drug' and 'blockbuster' that could be superior to current GLP-1s.

AI is expected to create massive opportunities in healthcare for companies like Eli Lilly, particularly for services like 'Lilly Direct'. However, significant regulatory hurdles in Western countries are a key risk that could slow down monetization.

Significant advertising spend on the new drug EpGliss suggests high expectations as a future revenue driver. The launch and market reception are critical indicators of the company's growth pipeline and future earnings potential.

The speaker's bearish view on GLP-1 drugs, due to their perceived negative impact on human drive, poses a long-term, non-financial risk to the company as part of the broader sector.

HIMS made a very smart strategic decision to never offer compounded versions of Lilly's drug, which is seen as a key advantage and de-risking factor, as it avoids conflict with the 'jewel of healthcare in America'.

At the forefront of the lucrative weight-loss drug market. Its drug, retatrutide, was singled out as a potential trillion-dollar drug. Potential new regulations restricting competition would be a massive bullish event.

The discussion of GLP-1 drugs' measurable public health impact signals a large and growing market, which could be a long-term tailwind for the pharmaceutical companies that dominate this space, such as Eli Lilly.

The speaker is very bullish, predicting the weight loss market will 'likely belong to Lilly towards year-end 2026' due to its superior product pipeline, particularly its upcoming drug Ritatrudide.

Mentioned as a 'Big Pharma' company defending its drug patents against compounding pharmacies like Hims. Its drug pipeline, including future drug retatrutide, could make current legal battles obsolete.

The speaker is extremely bullish, predicting LLY will 'own the entire market' for weight-loss drugs by late 2026 with its next-generation drug, retatrutide, making it a better long-term investment than NVO.

Considered to be 'winning the weight loss drug wars' after reporting earnings and revenue that crushed expectations and guiding for 25% revenue growth.